Author
Listed:
- Jianming Han
(Washington University in St Louis
University of Health Sciences and Pharmacy in St Louis and Washington University School of Medicine)
- Jingying Zhang
(Washington University School of Medicine
Washington University School of Medicine
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai)
- Antonina L. Nazarova
(University of Southern California
University of Southern California
University of Southern California)
- Sarah M. Bernhard
(Washington University in St Louis
University of Health Sciences and Pharmacy in St Louis and Washington University School of Medicine)
- Brian E. Krumm
(University of North Carolina School of Medicine)
- Lei Zhao
(Washington University in St Louis)
- Jordy Homing Lam
(University of Southern California
University of Southern California
University of Southern California)
- Vipin A. Rangari
(University of Health Sciences and Pharmacy in St Louis and Washington University School of Medicine)
- Susruta Majumdar
(Washington University in St Louis
University of Health Sciences and Pharmacy in St Louis and Washington University School of Medicine
Washington University in St Louis)
- David E. Nichols
(University of North Carolina)
- Vsevolod Katritch
(University of Southern California
University of Southern California
University of Southern California)
- Peng Yuan
(Washington University School of Medicine
Washington University School of Medicine
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai)
- Jonathan F. Fay
(University of Maryland Baltimore)
- Tao Che
(Washington University in St Louis
University of Health Sciences and Pharmacy in St Louis and Washington University School of Medicine
Washington University in St Louis)
Abstract
The κ-opioid receptor (KOR) represents a highly desirable therapeutic target for treating not only pain but also addiction and affective disorders1. However, the development of KOR analgesics has been hindered by the associated hallucinogenic side effects2. The initiation of KOR signalling requires the Gi/o-family proteins including the conventional (Gi1, Gi2, Gi3, GoA and GoB) and nonconventional (Gz and Gg) subtypes. How hallucinogens exert their actions through KOR and how KOR determines G-protein subtype selectivity are not well understood. Here we determined the active-state structures of KOR in a complex with multiple G-protein heterotrimers—Gi1, GoA, Gz and Gg—using cryo-electron microscopy. The KOR–G-protein complexes are bound to hallucinogenic salvinorins or highly selective KOR agonists. Comparisons of these structures reveal molecular determinants critical for KOR–G-protein interactions as well as key elements governing Gi/o-family subtype selectivity and KOR ligand selectivity. Furthermore, the four G-protein subtypes display an intrinsically different binding affinity and allosteric activity on agonist binding at KOR. These results provide insights into the actions of opioids and G-protein-coupling specificity at KOR and establish a foundation to examine the therapeutic potential of pathway-selective agonists of KOR.
Suggested Citation
Jianming Han & Jingying Zhang & Antonina L. Nazarova & Sarah M. Bernhard & Brian E. Krumm & Lei Zhao & Jordy Homing Lam & Vipin A. Rangari & Susruta Majumdar & David E. Nichols & Vsevolod Katritch & P, 2023.
"Ligand and G-protein selectivity in the κ-opioid receptor,"
Nature, Nature, vol. 617(7960), pages 417-425, May.
Handle:
RePEc:nat:nature:v:617:y:2023:i:7960:d:10.1038_s41586-023-06030-7
DOI: 10.1038/s41586-023-06030-7
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:617:y:2023:i:7960:d:10.1038_s41586-023-06030-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.